Abbott Labs's most recent trend suggests a bullish bias. One trading opportunity on Abbott Labs is a Bull Put Spread using a strike $100.00 short put and a strike $95.00 long put offers a potential 19.9% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $100.00 by expiration. The full premium credit of $0.83 would be kept by the premium seller. The risk of $4.17 would be incurred if the stock dropped below the $95.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Abbott Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Abbott Labs is bullish.
The RSI indicator is at 58.53 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Abbott Labs
Becton Dickinson Earnings Top, But BDX Stock Falls On Weak Sales
Thu, 06 Aug 2020 20:21:08 +0000
Becton Dickinson earnings beat views, but the coronavirus test maker missed on revenue and gave weak full-year guidance below expectations. Shares tumbled out of a buy zone early Thursday,
Biotechs Continue Strength Abbott Labs Still In Buy Zone
Wed, 05 Aug 2020 14:20:12 +0000
Abbott Labs still in buy zone from 100.10 buy point.
3 Charts That Suggest Sin Stocks Are Headed Higher
Tue, 04 Aug 2020 16:44:22 +0000
Spending on leisure and vice has remained high in recent months, making this sector one to watch during this period of uncertainty.
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
Tue, 04 Aug 2020 13:00:00 +0000
Abbott (NYSE: ABT) today announced first enrollments in the TactiFlex PAF IDE study to evaluate a new device to treat people suffering from paroxysmal atrial fibrillation (PAF), a type of irregular heartbeat. The study will evaluate the performance of the investigational TactiFlex™ Ablation Catheter, Sensor Enabled™ (SE) for people whose atrial fibrillation (AFib) symptoms are unable to be managed by medication.
3 Safe Stocks to Hold Through the Next Market Crash
Sat, 01 Aug 2020 10:44:00 +0000
Abbott Laboratories (NYSE: ABT) makes for a terrific investment for many reasons. For long-term investors, it starts with the Illinois-based company's rich history of dividend growth. Abbott is well on its way to becoming a Dividend King in a couple of years.The dividend currently yields about 1.4% annually, a bit short of the S&P 500 average of 2%.
Also on Market Tamer…
Follow Us on Facebook